Clinical trial
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate t
This study will assess the safety and efficacy of secukinumab compared to placebo in patients that have moderate to severe, chronic, plaque-type psoriasis.
| Category | Value |
|---|---|
| Date last updated at source | 2016-01-19 |
| Study type(s) | Interventional |
| Expected enrolment | 738 |
| Study start date | 2013-04-01 |
| Estimated primary completion date | 2013-04-01 |